BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, February 12, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 5, 2007
View Archived Issues
Recent patents disclose novel antidiabetic agents
Read More
Recent patents claim novel agents for obesity and metabolic disorders
Read More
Amgen identifies new CXCR3 antagonists with potential in autoimmune disorders
Read More
First patient enrolled in Akela Pharma phase IIb CGRP trial in asthma
Read More
Medivir recovers MIV-210 licensing rights and partners with Noken
Read More
Rivaroxaban prevents venous thromboembolism in hip replacement setting
Read More
Peplin completes Australasian actinic keratosis trial enrollment
Read More
New therapeutic agents for cancer covered in recent patent literature
Read More
Boehringer Ingelheim offers Apotex nevirapine license in developing countries
Read More
DMC recommends continuation of Isotechnika's phase IIb kidney transplant trial
Read More
Almirall completes acquisition of Hermal
Read More
ExonHit and Allergan's EHT/AGN-001 to begin phase I trials
Read More
Novel c-Met inhibitors described by Pfizer
Read More
Antisense inhibition of the growth hormone receptor effective in a model of retinopathy in vivo
Read More
Vical initiates phase I trial of Vaxfectin-formulated pDNA influenza vaccine
Read More
Access licenses MuGuard to SpePharm in Europe
Read More
FDA approves multiple day dosing of MGI Pharma and Helsinn's Aloxi injection
Read More
Quark extends siRNA compound research agreement with SUNY Buffalo
Read More
Nexavar sNDA granted FDA priority review for liver cancer indication
Read More
Positive results for Bayer and Onyx's Asia-Pacific phase III trial of Nexavar
Read More
Jerini regains North American marketing rights to icatibant in hereditary angioedema
Read More
Positive results from second phase III clinical trial of NeurogesX's dermal patch in PHN
Read More
Cubicin expanded indication approved in Europe
Read More
